Developments in personalized therapy for metastatic renal cell carcinoma
Author:
Affiliation:
1. Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
2. Department of Urology, Shiga University of Medical Science, Otsu, Japan
Funder
JSPS KAKENHI
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Oncology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14737140.2022.2075347
Reference48 articles.
1. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
2. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
3. Biomarkers to predict prognosis and response to checkpoint inhibitors
4. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
5. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Editorial comment to Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second‐line treatment with tyrosine kinase inhibitor following first‐line immune‐oncology combination therapy;International Journal of Urology;2024-01-31
2. Comprehensive analysis of necroptosis-related lncRNA signature with potential implications in tumor heterogeneity and prediction of prognosis in clear cell renal cell carcinoma;European Journal of Medical Research;2023-07-14
3. Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population;Expert Review of Anticancer Therapy;2023-04-10
4. Editorial Comment on Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non‐clear cell renal cell carcinoma: Real‐world data from a Japanese multicenter retrospective study;International Journal of Urology;2023-01-18
5. RBM4 inhibits the growth of clear cell renal cell carcinoma by enhancing the stability of p53 mRNA;Molecular Carcinogenesis;2022-12-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3